Polycythemia vera (PV) treatment with interferon α (IFNα) is frequently limited by dose related toxicity. PV CD34 + cells are characterized by over expression of Bcl-xL which can be antagonized by ABT-737 leading to apoptosis. We explored the effects of ABT-737 and IFNα on PV hematopoisis.
Introduction
Therapeutic options in polycythemia vera (PV) include phlebotomy, low dose aspirin hydroxyurea and interferon α (IFNα) (1) . IFNα effectively controls erythrocytosis and thrombocytosis (2) and can correct the marrow morphology, induce cytogenetic remissions, reduce the JAK2V617F allele burden and revert monoclonal to polyclonal hematopoiesis (3-8). Our laboratory has reported that IFNα selectively eliminates JAK2V617F hematopoietic progenitor cells (HPC) (9) . IFNα use is limited by lack of accessibility and concern over therapy associated toxicity (10) . Since its toxicity is related to dose, we hypothesize that combinations of drugs to enhance the therapeutic effectiveness of IFNα might permit the administration of lower doses of IFNα .
Silva and colleagues reported that Bcl-xl was dysregulated in PV erythroblasts which might contribute to the development of erythrocytosis (11) . Similarly megakaryocytes (MK) are also characterized by over-expression of Bcl-xL (12) . This over expression of Bcl-xL is likely a down stream consequence of JAK2V617F (13) . ABT-737 is a small-molecule inhibitor that binds the antiapoptotic proteins, Bcl-2, and Bcl-xL, and promotes apoptosis (14) . Zeuner and coworkers and Will et al (15) (16) was detected using a nested allele-specific PCR as previously described (17) .
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Results and Discussion
As can be seen in Figure 1A however, was equivalent to that of 500 U/ml of IFN alone in eliminating JAK2V617F HPC.
Furthermore, the addition of ABT-737 was also capable of potentiating the ability of 500 U/ml of IFN to further reduce the proportion of JAK2V617F HPC. We have previously reported that the JAK2V617F homozygous HPC are more sensitive than JAK2V617F heterozygous HPCs to the in vitro actions of IFNα (9) . As can be seen in Figure 2C , ABT-737 was not effective in eliminating JAK2V617F homozygous HPC but did augment the activity of a low dose of IFN α to dramatically reducing the proportion of JAK2V617F homozygous HPC. In the 9 cases where JAK2V617F homozygous colonies were observed the addition of 200 U/ml of Peg-IFNα 2a plus 250 nM ABT-737 led to either the total elimination of such homozygous colonies or a marked reduction in their numbers.
IFNα therapy is interrupted frequently by dose related toxicity (2, 7-8, 10). Cessation of IFNα therapy ultimately leads to relapse of the underlying disease (18). The successful treatment of most
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From hematological malignancies requires the use of combinations of drugs. Our data suggests that combinations of low doses of IFNα and ABT-737 might serve as an effective means of treating PV patients. IFNα treatment activates caspase through p38 MAP kinase which activates Bax (8, 19). The activity of a combination of IFNα and ABT-737 observed in these studies, therefore, appears likely to be the consequence of the activation of caspase by two independent pathways. The results we observed with the combination of ABT-737 and Peg-IFNα 2a strongly suggests that this strategy might be an even more optimal approach for the treatment of MPN which merits further testing in the clinic. 
